Natalizumab for the treatment of relapsing multiple sclerosis

por Rudick, Richard A, Panzara, Michael A
Publicado 2008

Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA

por Radue, Ernst-Wilhelm, Sprenger, Till, Gaetano, Laura, Mueller-Lenke, Nicole, Cavalier, Steve, Thangavelu, Karthinathan, Panzara, Michael A., Donaldson, Jessica E., Woodward, Fiona M., Wuerfel, Jens, Wolinsky, Jerry S., Kappos, Ludwig
Publicado 2017

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

por Giovannoni, Gavin, Cohen, Jeffrey A., Coles, Alasdair J., Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W., Margolin, David H., Lake, Stephen L., Kaup, Susan M., Panzara, Michael A., Compston, D. Alastair S.
Publicado 2016

Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease

por Claassen, Daniel O., Corey-Bloom, Jody, Dorsey, E. Ray, Edmondson, Mary, Kostyk, Sandra K., LeDoux, Mark S., Reilmann, Ralf, Rosas, H. Diana, Walker, Francis, Wheelock, Vicki, Svrzikapa, Nenad, Longo, Kenneth A., Goyal, Jaya, Hung, Serena, Panzara, Michael A.
Publicado 2020

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS

por Arnold, Douglas L., Fisher, Elizabeth, Brinar, Vesna V., Cohen, Jeffrey A., Coles, Alasdair J., Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W., Stojanovic, Miroslav, Weiner, Howard L., Lake, Stephen L., Margolin, David H., Thomas, David R., Panzara, Michael A., Compston, D. Alastair S.
Publicado 2016

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

por Coles, Alasdair J., Cohen, Jeffrey A., Fox, Edward J., Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Schippling, Sven, Selmaj, Krzysztof W., Traboulsee, Anthony, Compston, D. Alastair S., Margolin, David H., Thangavelu, Karthinathan, Chirieac, Madalina C., Jody, Darlene, Xenopoulos, Panos, Hogan, Richard J., Panzara, Michael A., Arnold, Douglas L.
Publicado 2017

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

por Havrdova, Eva, Arnold, Douglas L., Cohen, Jeffrey A., Hartung, Hans-Peter, Fox, Edward J., Giovannoni, Gavin, Schippling, Sven, Selmaj, Krzysztof W., Traboulsee, Anthony, Compston, D. Alastair S., Margolin, David H., Thangavelu, Karthinathan, Rodriguez, Claudio E., Jody, Darlene, Hogan, Richard J., Xenopoulos, Panos, Panzara, Michael A., Coles, Alasdair J.
Publicado 2017